Literature DB >> 26108659

Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases.

Yufei Liu1, Brian M Alexander1, Yu-Hui Chen2, Margaret C Horvath1, Ayal A Aizer1, Elizabeth B Claus3,4, Ian F Dunn3, Alexandra J Golby3, Mark D Johnson3, Scott Friesen1, Edward G Mannarino1, Matthew Wagar1, Fred L Hacker1, Nils D Arvold5.   

Abstract

Patients with limited brain metastases are often candidates for stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT). Among patients who receive SRS, the likelihood and timing of salvage WBRT or SRS remains unclear. We examined rates of salvage WBRT or SRS among 180 patients with 1-4 newly diagnosed brain metastases who received index SRS from 2008-2013. Competing risks multivariable analysis was used to examine factors associated with time to WBRT. Patients had non-small cell lung (53 %), melanoma (23 %), breast (10 %), renal (6 %), or other (8 %) cancers. Median age was 62 years. Patients received index SRS to 1 (60 %), 2 (21 %), 3 (13 %), or 4 (7 %) brain metastases. Median survival after SRS was 9.7 months (range, 0.3-67.6 months). No further brain-directed radiotherapy was delivered after index SRS in 55 % of patients. Twenty-seven percent of patients ever received salvage WBRT, and 30 % ever received salvage SRS; 12 % of patients received both salvage WBRT and salvage SRS. Median time to salvage WBRT or salvage SRS were 5.6 and 6.1 months, respectively. Age ≤60 years (adjusted hazard ratio [AHR] = 2.80; 95 % CI 1.05-7.51; P = 0.04) and controlled/absent extracranial disease (AHR = 6.76; 95 % CI 1.60-28.7; P = 0.01) were associated with shorter time to salvage WBRT. Isolated brain progression caused death in only 11 % of decedents. In summary, most patients with 1-4 brain metastases receiving SRS never require salvage WBRT or SRS, and the remainder do not require salvage treatment for a median of 6 months.

Entities:  

Keywords:  Brain metastases; Cause of death; Salvage; Stereotactic radiosurgery; Whole brain radiotherapy

Mesh:

Year:  2015        PMID: 26108659     DOI: 10.1007/s11060-015-1855-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

Review 1.  The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.

Authors:  Minesh P Mehta; May N Tsao; Timothy J Whelan; David E Morris; James A Hayman; John C Flickinger; Michael Mills; C Leland Rogers; Luis Souhami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases.

Authors:  George Rodrigues; Andrew Warner; Jaap Zindler; Ben Slotman; Frank Lagerwaard
Journal:  Radiother Oncol       Date:  2014-01-17       Impact factor: 6.280

4.  Use of stereotactic radiosurgery for brain metastases from non-small cell lung cancer in the United States.

Authors:  Lia M Halasz; Jane C Weeks; Bridget A Neville; Nathan Taback; Rinaa S Punglia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-09       Impact factor: 7.038

5.  Radiosurgery for brain metastases: is whole brain radiotherapy necessary?

Authors:  P K Sneed; K R Lamborn; J M Forstner; M W McDermott; S Chang; E Park; P H Gutin; T L Phillips; W M Wara; D A Larson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

6.  Clinical outcomes of patients treated with a second course of stereotactic radiosurgery for locally or regionally recurrent brain metastases after prior stereotactic radiosurgery.

Authors:  Daniel H Kim; Timothy E Schultheiss; Eric H Radany; Behnam Badie; Richard D Pezner
Journal:  J Neurooncol       Date:  2013-06-28       Impact factor: 4.130

7.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

Authors:  Masaaki Yamamoto; Toru Serizawa; Takashi Shuto; Atsuya Akabane; Yoshinori Higuchi; Jun Kawagishi; Kazuhiro Yamanaka; Yasunori Sato; Hidefumi Jokura; Shoji Yomo; Osamu Nagano; Hiroyuki Kenai; Akihito Moriki; Satoshi Suzuki; Yoshihisa Kida; Yoshiyasu Iwai; Motohiro Hayashi; Hiroaki Onishi; Masazumi Gondo; Mitsuya Sato; Tomohide Akimitsu; Kenji Kubo; Yasuhiro Kikuchi; Toru Shibasaki; Tomoaki Goto; Masami Takanashi; Yoshimasa Mori; Kintomo Takakura; Naokatsu Saeki; Etsuo Kunieda; Hidefumi Aoyama; Suketaka Momoshima; Kazuhiro Tsuchiya
Journal:  Lancet Oncol       Date:  2014-03-10       Impact factor: 41.316

8.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

9.  Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis.

Authors:  Giuseppe Minniti; Enrico Clarke; Gaetano Lanzetta; Mattia Falchetto Osti; Guido Trasimeni; Alessandro Bozzao; Andrea Romano; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2011-05-15       Impact factor: 3.481

10.  Clinical and economic outcomes of patients with brain metastases based on symptoms: an argument for routine brain screening of those treated with upfront radiosurgery.

Authors:  Scott C Lester; Glen B Taksler; J Griff Kuremsky; John T Lucas; Diandra N Ayala-Peacock; David M Randolph; J Daniel Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan
Journal:  Cancer       Date:  2013-10-21       Impact factor: 6.921

View more
  4 in total

Review 1.  Updates in the management of brain metastases.

Authors:  Nils D Arvold; Eudocia Q Lee; Minesh P Mehta; Kim Margolin; Brian M Alexander; Nancy U Lin; Carey K Anders; Riccardo Soffietti; D Ross Camidge; Michael A Vogelbaum; Ian F Dunn; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2016-08       Impact factor: 12.300

2.  Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy.

Authors:  Gabriella Frisk; Beatrice Tinge; Sara Ekberg; Sandra Eloranta; L Magnus Bäcklund; Elisabet Lidbrink; Karin E Smedby
Journal:  Breast Cancer Res Treat       Date:  2017-08-22       Impact factor: 4.872

3.  Brain metastasis reirradiation in patients with advanced breast cancer.

Authors:  Zhou Huang; Bing Sun; Ge Shen; Lei Cha; Xiangying Meng; Junliang Wang; Zhenshan Zhou; Shikai Wu
Journal:  J Radiat Res       Date:  2016-10-05       Impact factor: 2.724

Review 4.  A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future Research.

Authors:  Thomas C Booth; Gerard Thompson; Helen Bulbeck; Florien Boele; Craig Buckley; Jorge Cardoso; Liane Dos Santos Canas; David Jenkinson; Keyoumars Ashkan; Jack Kreindler; Nicky Huskens; Aysha Luis; Catherine McBain; Samantha J Mills; Marc Modat; Nick Morley; Caroline Murphy; Sebastian Ourselin; Mark Pennington; James Powell; David Summers; Adam D Waldman; Colin Watts; Matthew Williams; Robin Grant; Michael D Jenkinson
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.